跳到正文
BioPharm International·· 5 天前AI 评分27

下一代生物偶联物设计需要正交分析方法

Next-Generation Bioconjugate Design Calls for an Orthogonal Analytical Approach

AI 导读

随着生物偶联物日益复杂,专家讨论正交分析方法如何填补表征缺口。文章聚焦下一代生物偶联物设计对正交分析策略的需求,未涉及具体药品、批次或监管文件。

正文 · 原文

News|Articles|November 17, 2026

As bioconjugates grow more complex, experts discuss how orthogonal analytical methods fill characterization gaps.

Related to this article

Concept of collaboration | Image credit: © thodonal - © thodonal - stock.adobe.com

November 18th, 2026

mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.

Read more

Advancing Healthcare with CAR T-Cell Therapy: A New Frontier in Medicine | Image credit: © Funny - © Funny - stock.adobe.com

November 18th, 2026

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Read more

Fundus photograph of a human retina showing the pale optic disc on the left, branching red blood vessels and a darker spot at the center of the macula. | Image Credit: © Panama - stock.adobe.com

November 18th, 2026

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.

Read more

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com

November 18th, 2026

The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.

Read more

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing

November 17th, 2026

FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.

Read more

Film X-ray shoulder radiograph show Enchondroma disease at arm bone. Enchondrama is a benign tumor of cartilage grow within bone and expand it. Highlight on mass lesion. Medical oncology concept | Image credit: © Joel bubble ben - © Joel bubble ben - stock.adobe.com

November 17th, 2026

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Read more

Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck

November 17th, 2026

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Read more

3D illustration of blue Y-shaped antibodies with yellow-green tips floating near the textured green surface of a large cell, against a blurred blue background. | Image Credit: © ustas - stock.adobe.com

November 17th, 2026

Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.

Read more

来源:BioPharm International · biopharminternational.com